FDA
-
-
-
-
-
-
-
Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs
-
-
-
-
-
-
-
Korro Bio Inc. (KRRO) PT Lowered to $100 at H.C. Wainwright
-
-
-
-
-
-
-
Korro (KRRO) Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency
-
335,221 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


